首页 > 最新文献

Journal of Clinical and Experimental Hematopathology最新文献

英文 中文
Two cases of primary diffuse large B-cell lymphoma of the CNS associated with t(8;14)(q24;q32) or t(3;14)(q27;q32) identified by G-banding and fluorescence in situ hybridization applied to metaphase spreads. 2例CNS原发性弥漫性大b细胞淋巴瘤与t(8;14)(q24;q32)或t(3;14)(q27;q32)相关,g带和荧光原位杂交应用于中期扩散。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2022-12-28 DOI: 10.3960/jslrt.22019
Hitoshi Ohno, Fumiyo Maekawa, Misumi Nakagawa, Yoshinari Chagi, Miho Nakagawa, Chiyuki Kishimori, Katsuhiro Fukutsuka, Masahiko Hayashida, Kayo Takeoka, Wataru Maruyama, Naoya Ukyo, Shinji Sumiyoshi

We describe two patients with primary diffuse large B-cell lymphoma of the central nervous system (PCNS-DLBCL). The first patient (case 1) was a woman in her late 70s who presented with a tumor in the left frontal lobe, whereas the second patient (case 2) was a man in his early 70s who presented with a left frontal lobe tumor associated with intratumoral hemorrhage. The histopathology of the tumor specimen disclosed the proliferation of large cells with centroblastic (case 1) or immunoblastic/plasmablastic (case 2) cytomorphology and an accumulation of the tumor cells within the perivascular space. The cells in both cases were positive for CD20, CD79a, BCL6, IRF4/MUM1, MYC, and BCL2 and negative for CD5 and CD10. G-banding revealed t(8;14)(q24;q32) in case 1, and the tetraploid-range karyotype including two or three copies of der(3)t(3;14)(q27;q32) and der(14)t(3;14)(q27;q32) in case 2. Fluorescence in situ hybridization applied to metaphase spreads confirmed colocalization of MYC and IGH (case 1) and BCL6 and IGH (case 2) hybridization signals on the relevant derivative chromosomes. Case 1 carried the MYD88L265P mutation. This case report provides clear evidence for the occurrence of t(8;14)(q24;q32) and t(3;14)(q27;q32) in PCNS-DLBCL using metaphase-based cytogenetic analysis.

我们报告了两例原发性中枢神经系统弥漫性大b细胞淋巴瘤(PCNS-DLBCL)。第一位患者(病例1)是一位70多岁的女性,左侧额叶有肿瘤,而第二位患者(病例2)是一位70多岁的男性,左侧额叶有肿瘤并伴有肿瘤内出血。肿瘤标本的组织病理学显示,大细胞增生,具有成中心细胞(病例1)或免疫母细胞/浆母细胞(病例2)的细胞形态,肿瘤细胞在血管周围空间内积聚。这两种情况下的细胞CD20、CD79a、BCL6、IRF4/MUM1、MYC和BCL2阳性,CD5和CD10阴性。g -band显示病例1为t(8;14)(q24;q32),四倍体核型包括病例2为der(3)t(3;14)(q27;q32)和der(14)t(3;14)(q27;q32)的2个或3个拷贝。应用中期扩散的荧光原位杂交证实了MYC和IGH(病例1)以及BCL6和IGH(病例2)杂交信号在相关衍生染色体上的共定位。病例1携带MYD88L265P突变。本病例报告通过基于中期的细胞遗传学分析,为PCNS-DLBCL中出现t(8;14)(q24;q32)和t(3;14)(q27;q32)提供了明确的证据。
{"title":"Two cases of primary diffuse large B-cell lymphoma of the CNS associated with t(8;14)(q24;q32) or t(3;14)(q27;q32) identified by G-banding and fluorescence in situ hybridization applied to metaphase spreads.","authors":"Hitoshi Ohno,&nbsp;Fumiyo Maekawa,&nbsp;Misumi Nakagawa,&nbsp;Yoshinari Chagi,&nbsp;Miho Nakagawa,&nbsp;Chiyuki Kishimori,&nbsp;Katsuhiro Fukutsuka,&nbsp;Masahiko Hayashida,&nbsp;Kayo Takeoka,&nbsp;Wataru Maruyama,&nbsp;Naoya Ukyo,&nbsp;Shinji Sumiyoshi","doi":"10.3960/jslrt.22019","DOIUrl":"https://doi.org/10.3960/jslrt.22019","url":null,"abstract":"<p><p>We describe two patients with primary diffuse large B-cell lymphoma of the central nervous system (PCNS-DLBCL). The first patient (case 1) was a woman in her late 70s who presented with a tumor in the left frontal lobe, whereas the second patient (case 2) was a man in his early 70s who presented with a left frontal lobe tumor associated with intratumoral hemorrhage. The histopathology of the tumor specimen disclosed the proliferation of large cells with centroblastic (case 1) or immunoblastic/plasmablastic (case 2) cytomorphology and an accumulation of the tumor cells within the perivascular space. The cells in both cases were positive for CD20, CD79a, BCL6, IRF4/MUM1, MYC, and BCL2 and negative for CD5 and CD10. G-banding revealed t(8;14)(q24;q32) in case 1, and the tetraploid-range karyotype including two or three copies of der(3)t(3;14)(q27;q32) and der(14)t(3;14)(q27;q32) in case 2. Fluorescence in situ hybridization applied to metaphase spreads confirmed colocalization of MYC and IGH (case 1) and BCL6 and IGH (case 2) hybridization signals on the relevant derivative chromosomes. Case 1 carried the MYD88<sup>L265P</sup> mutation. This case report provides clear evidence for the occurrence of t(8;14)(q24;q32) and t(3;14)(q27;q32) in PCNS-DLBCL using metaphase-based cytogenetic analysis.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"62 4","pages":"242-248"},"PeriodicalIF":1.5,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9c/0b/jslrt-62-242.PMC9898718.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10690103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Severe autoimmune pancytopenia after autologous hematopoietic stem cell transplantation for Hodgkin lymphoma. 自体造血干细胞移植治疗霍奇金淋巴瘤后严重自身免疫性全血细胞减少症。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2022-12-28 DOI: 10.3960/jslrt.22006
Yuta Fukui, Akira Honda, Hirofumi Takano, Takafumi Obo, Hideaki Mizuno, Yosuke Masamoto, Mineo Kurokawa

Autoimmune pancytopenia is rarely seen with Hodgkin lymphoma, and only one pediatric case of pancytopenia after autologous hematopoietic stem cell transplantation (HSCT) has been reported. We herein report a case of autoimmune pancytopenia that developed after autologous HSCT for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). A 56-year-old Japanese woman underwent autologous HSCT for NLPHL. She developed autoimmune pancytopenia seven months after autologous HSCT. In this case, PSL was effective, and the blood cell counts normalized completely. However, the patient suffered from a fatal infection, probably because of immunosuppression caused by prolonged administration of PSL, as well as a history of several chemotherapies and autologous HSCT. To our knowledge, this is the first adult case of autoimmune pancytopenia after autologous HSCT for Hodgkin lymphoma. To further validate the optimal treatment strategy for autoimmune cytopenia after autologous HSCT, more cases are necessary.

自身免疫性全血细胞减少症在霍奇金淋巴瘤中很少见,仅报道了一例自体造血干细胞移植(HSCT)后全血细胞减少症的儿童病例。我们在此报告一例自身免疫性全血细胞减少症,在自体造血干细胞移植后发展为结节性淋巴细胞显性霍奇金淋巴瘤(NLPHL)。一名56岁的日本女性因NLPHL接受了自体造血干细胞移植。她在自体造血干细胞移植后7个月出现自身免疫性全血细胞减少症。在这种情况下,PSL是有效的,血细胞计数完全正常化。然而,患者发生了致命的感染,可能是由于长期服用PSL引起的免疫抑制,以及多次化疗和自体造血干细胞移植的历史。据我们所知,这是首例成人霍奇金淋巴瘤自体造血干细胞移植后自身免疫性全血细胞减少症。为了进一步验证自体造血干细胞移植后自身免疫性细胞减少的最佳治疗策略,需要更多的病例。
{"title":"Severe autoimmune pancytopenia after autologous hematopoietic stem cell transplantation for Hodgkin lymphoma.","authors":"Yuta Fukui,&nbsp;Akira Honda,&nbsp;Hirofumi Takano,&nbsp;Takafumi Obo,&nbsp;Hideaki Mizuno,&nbsp;Yosuke Masamoto,&nbsp;Mineo Kurokawa","doi":"10.3960/jslrt.22006","DOIUrl":"https://doi.org/10.3960/jslrt.22006","url":null,"abstract":"<p><p>Autoimmune pancytopenia is rarely seen with Hodgkin lymphoma, and only one pediatric case of pancytopenia after autologous hematopoietic stem cell transplantation (HSCT) has been reported. We herein report a case of autoimmune pancytopenia that developed after autologous HSCT for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). A 56-year-old Japanese woman underwent autologous HSCT for NLPHL. She developed autoimmune pancytopenia seven months after autologous HSCT. In this case, PSL was effective, and the blood cell counts normalized completely. However, the patient suffered from a fatal infection, probably because of immunosuppression caused by prolonged administration of PSL, as well as a history of several chemotherapies and autologous HSCT. To our knowledge, this is the first adult case of autoimmune pancytopenia after autologous HSCT for Hodgkin lymphoma. To further validate the optimal treatment strategy for autoimmune cytopenia after autologous HSCT, more cases are necessary.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"62 4","pages":"217-221"},"PeriodicalIF":1.5,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/9d/jslrt-62-217.PMC9898711.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10700335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Acute undifferentiated leukemia limited to neck lymph nodes and a large mediastinal mass. 急性未分化白血病局限于颈部淋巴结和大纵隔肿块。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2022-12-28 DOI: 10.3960/jslrt.22012
Kenta Hayashino, Masayuki Matsuda, Keigo Fujishita, Jun Iwata, Miki Mizobuchi, Munenori Uemura, Kenji Yorita, Akiko Maeshima, Toshi Imai

In the 2016 update of the World Health Organization (WHO) classification of myeloid neoplasms, acute undifferentiated leukemia (AUL) was defined by a lack of lineage-specific markers. AUL has very poor prognosis and no established therapies due to its rarity. We report a case of a 31-year-old man with AUL who showed complete molecular response to an acute lymphoblastic leukemia (ALL)-based regimen and received allogeneic hematopoietic stem cell transplantation. The patient's blast cells were CD7-positive and localized to lymph nodes in the neck and to a large mediastinal mass; there was also rearrangement of the T-cell receptor delta locus. Although the tumor showed characteristics of T-cell lymphoblastic lymphoma, it was categorized as AUL based on WHO classification. This case suggests that a high-intensity conditioning regimen could be effective for rare cases of AUL that present only in the extramedullary mass, and chemotherapy for AUL should be selected based on the characteristics of the blasts.

在2016年更新的世界卫生组织(WHO)髓系肿瘤分类中,急性未分化白血病(AUL)被定义为缺乏谱系特异性标记物。由于其罕见,AUL预后很差,没有成熟的治疗方法。我们报告了一例31岁的AUL患者,他对急性淋巴细胞白血病(ALL)治疗方案表现出完全的分子反应,并接受了异基因造血干细胞移植。患者的母细胞cd7阳性,并局限于颈部淋巴结和大纵隔肿块;t细胞受体δ位点也发生了重排。虽然肿瘤表现出t细胞淋巴母细胞淋巴瘤的特征,但根据WHO的分类将其归类为AUL。本病例提示,对于仅存在于髓外肿块的罕见AUL病例,高强度调理方案可能有效,并且应根据原细胞的特征选择AUL的化疗方案。
{"title":"Acute undifferentiated leukemia limited to neck lymph nodes and a large mediastinal mass.","authors":"Kenta Hayashino,&nbsp;Masayuki Matsuda,&nbsp;Keigo Fujishita,&nbsp;Jun Iwata,&nbsp;Miki Mizobuchi,&nbsp;Munenori Uemura,&nbsp;Kenji Yorita,&nbsp;Akiko Maeshima,&nbsp;Toshi Imai","doi":"10.3960/jslrt.22012","DOIUrl":"https://doi.org/10.3960/jslrt.22012","url":null,"abstract":"<p><p>In the 2016 update of the World Health Organization (WHO) classification of myeloid neoplasms, acute undifferentiated leukemia (AUL) was defined by a lack of lineage-specific markers. AUL has very poor prognosis and no established therapies due to its rarity. We report a case of a 31-year-old man with AUL who showed complete molecular response to an acute lymphoblastic leukemia (ALL)-based regimen and received allogeneic hematopoietic stem cell transplantation. The patient's blast cells were CD7-positive and localized to lymph nodes in the neck and to a large mediastinal mass; there was also rearrangement of the T-cell receptor delta locus. Although the tumor showed characteristics of T-cell lymphoblastic lymphoma, it was categorized as AUL based on WHO classification. This case suggests that a high-intensity conditioning regimen could be effective for rare cases of AUL that present only in the extramedullary mass, and chemotherapy for AUL should be selected based on the characteristics of the blasts.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"62 4","pages":"222-225"},"PeriodicalIF":1.5,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f6/e3/jslrt-62-222.PMC9898720.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10700334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diffuse large B-cell lymphoma in the course of systemic sarcoidosis: A case report and review of 30 Japanese patients with sarcoidosis-lymphoma syndrome. 弥漫性大b细胞淋巴瘤伴全身性结节病:30例日本结节病-淋巴瘤综合征病例报告及复习。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2022-12-28 DOI: 10.3960/jslrt.22015
Toshihiko Matsuo, Takehiro Tanaka, Rika Omote, Toshiaki Okada, Kenji Notohara, Kazuya Okada

We report a patient with sarcoidosis who developed diffuse large B-cell lymphoma. A 71-year-old woman with persistent cough was diagnosed pathologically with sarcoidosis by resection of the right upper lung lobe with a nodule after an unsuccessful attempt of transbronchial needle aspiration for mediastinal lymphadenopathy. She was referred for an eye examination and found to have spotty retinal degeneration on the lower fundi of both eyes, together with residual macular edema and vitreous opacity in the left eye. At 76 years, she underwent cataract surgery and vitrectomy to gain a visual acuity of 0.6 in the left eye. At 77 years, she developed a cough and fever, and showed leukopenia and thrombocytopenia. Computed tomography showed multiple small nodular lesions in both lungs, and bilateral hilar, mediastinal, and hepatic lymphadenopathy. Fluorodeoxyglucose positron emission tomography demonstrated high uptake in the liver, spleen, pancreatic head, and lymph nodes. Bone marrow biopsy was intact, but liver biopsy revealed anomalous large lymphoid cells in the sinusoids which were positive for CD20 and showed a high Ki-67 index, leading to the diagnosis of diffuse large B-cell lymphoma. Chemotherapy with 8 courses of THP-COP (cyclophosphamide, pirarubicin, vincristine, and prednisolone) with rituximab, followed by intrathecal injection of methotrexate, cytarabine, and dexamethasone, resulted in complete remission. She maintained complete remission for 10 years until 88 years old at present. The literature review found 30 patients, including this case, who developed lymphoma in the course of sarcoidosis. A novel pathological diagnosis is required in the setting of acute symptomatic changes and novel lesions on imaging in patients with sarcoidosis.

我们报告一位结节病并发弥漫性大b细胞淋巴瘤的患者。一位71岁的女性,持续咳嗽,在尝试经支气管穿刺治疗纵隔淋巴结病失败后,通过切除右上肺叶结节,病理诊断为结节病。转介眼科检查,发现双眼下眼底有点状视网膜变性,左眼残余黄斑水肿及玻璃体混浊。76岁时,她接受了白内障手术和玻璃体切除术,使左眼视力恢复到0.6。77岁时,她出现咳嗽和发烧,并表现出白细胞减少和血小板减少。计算机断层扫描显示双肺多发小结节病变,双肺门、纵隔和肝淋巴结病变。氟脱氧葡萄糖正电子发射断层扫描显示肝脏、脾脏、胰头和淋巴结有高摄取。骨髓活检未见异常,肝活检示窦内异常大淋巴细胞CD20阳性,Ki-67指数高,诊断为弥漫性大b细胞淋巴瘤。8疗程的THP-COP(环磷酰胺、吡柔比星、长春新碱和强的松龙)联合利妥昔单抗化疗,随后鞘内注射甲氨蝶呤、阿糖胞苷和地塞米松,导致完全缓解。她完全缓解了10年,直到现在88岁。文献回顾发现包括本病例在内的30例患者在结节病过程中发生淋巴瘤。一个新的病理诊断是需要在设置急性症状变化和新的病变影像学结节病患者。
{"title":"Diffuse large B-cell lymphoma in the course of systemic sarcoidosis: A case report and review of 30 Japanese patients with sarcoidosis-lymphoma syndrome.","authors":"Toshihiko Matsuo,&nbsp;Takehiro Tanaka,&nbsp;Rika Omote,&nbsp;Toshiaki Okada,&nbsp;Kenji Notohara,&nbsp;Kazuya Okada","doi":"10.3960/jslrt.22015","DOIUrl":"https://doi.org/10.3960/jslrt.22015","url":null,"abstract":"<p><p>We report a patient with sarcoidosis who developed diffuse large B-cell lymphoma. A 71-year-old woman with persistent cough was diagnosed pathologically with sarcoidosis by resection of the right upper lung lobe with a nodule after an unsuccessful attempt of transbronchial needle aspiration for mediastinal lymphadenopathy. She was referred for an eye examination and found to have spotty retinal degeneration on the lower fundi of both eyes, together with residual macular edema and vitreous opacity in the left eye. At 76 years, she underwent cataract surgery and vitrectomy to gain a visual acuity of 0.6 in the left eye. At 77 years, she developed a cough and fever, and showed leukopenia and thrombocytopenia. Computed tomography showed multiple small nodular lesions in both lungs, and bilateral hilar, mediastinal, and hepatic lymphadenopathy. Fluorodeoxyglucose positron emission tomography demonstrated high uptake in the liver, spleen, pancreatic head, and lymph nodes. Bone marrow biopsy was intact, but liver biopsy revealed anomalous large lymphoid cells in the sinusoids which were positive for CD20 and showed a high Ki-67 index, leading to the diagnosis of diffuse large B-cell lymphoma. Chemotherapy with 8 courses of THP-COP (cyclophosphamide, pirarubicin, vincristine, and prednisolone) with rituximab, followed by intrathecal injection of methotrexate, cytarabine, and dexamethasone, resulted in complete remission. She maintained complete remission for 10 years until 88 years old at present. The literature review found 30 patients, including this case, who developed lymphoma in the course of sarcoidosis. A novel pathological diagnosis is required in the setting of acute symptomatic changes and novel lesions on imaging in patients with sarcoidosis.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"62 4","pages":"226-237"},"PeriodicalIF":1.5,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1e/48/jslrt-62-226.PMC9898715.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10695884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Immunohistochemistry for IRTA1 and MNDA helps differentiate gastric MALT lymphoma from chronic gastritis/reactive lymphocyte hyperplasia. 免疫组织化学检测IRTA1和MNDA有助于区分胃MALT淋巴瘤与慢性胃炎/反应性淋巴细胞增生。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2022-12-28 DOI: 10.3960/jslrt.22021
Yoshiyuki Ayada, Takuro Igawa, Yusuke Naoi, Kyosuke Horikawa, Tetsuya Tabata, Takehiro Tanaka, Tadashi Yoshino

It is difficult to histologically differentiate extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) from chronic gastritis (CG)/ reactive lymphoid hyperplasia (RLH). To determine whether immunohistochemistry for IRTA1 and MNDA can differentiate gastric MALT lymphoma from CG/RLH, we investigated 81 stomach biopsy specimens [Wotherspoon grade (WG) 1, 11 cases; WG 2, 9 cases; WG 3, 20 cases; WG 4, 31 cases; and WG 5, 10 cases]. According to a previously reported algorithm involving PCR for immunoglobulin heavy (IgH) chain locus rearrangement, all 81 cases were divided into three groups: CG/RLH (55 cases), MALT lymphoma (19 cases) groups, and IgH undetectable group (7 cases). We analyzed the CG/RLH and MALT lymphoma groups. The median percentage of IRTA1-positive cells was 0% (range 0%-90.6%) in the CG/RLH group and 43.5% (range 0%-97.6%) in the MALT lymphoma group (p < 0.0001). The median percentage of MNDA-positive cells was 32.4% (range 0%-97.6%) in the CG/RLH group and 55.1% (range 0%-97.6%) in the MALT lymphoma group (p = 0.0044). These results indicate that immunohistochemistry for IRTA1 and MNDA can help differentiate gastric MALT lymphoma from CG/RLH.

从组织学上很难区分结外粘膜相关淋巴组织边缘区淋巴瘤(MALT淋巴瘤)与慢性胃炎(CG)/反应性淋巴样增生(RLH)。为了确定IRTA1和MNDA的免疫组化是否可以区分胃MALT淋巴瘤和CG/RLH,我们研究了81例胃活检标本[Wotherspoon分级(WG) 1,11例;WG 2,9例;WG 3,20例;WG 4,31例;WG 5,10例]。根据先前报道的免疫球蛋白重(IgH)链位点重排PCR算法,将81例患者分为CG/RLH组(55例)、MALT淋巴瘤组(19例)和IgH未检出组(7例)。我们分析了CG/RLH和MALT淋巴瘤组。irta1阳性细胞的中位数百分比在CG/RLH组为0%(范围为0%-90.6%),在MALT淋巴瘤组为43.5%(范围为0%-97.6%)(p < 0.0001)。在CG/RLH组中,mnda阳性细胞的中位数百分比为32.4%(范围0%-97.6%),在MALT淋巴瘤组中为55.1%(范围0%-97.6%)(p = 0.0044)。这些结果表明,IRTA1和MNDA的免疫组化可以帮助区分胃MALT淋巴瘤和CG/RLH。
{"title":"Immunohistochemistry for IRTA1 and MNDA helps differentiate gastric MALT lymphoma from chronic gastritis/reactive lymphocyte hyperplasia.","authors":"Yoshiyuki Ayada,&nbsp;Takuro Igawa,&nbsp;Yusuke Naoi,&nbsp;Kyosuke Horikawa,&nbsp;Tetsuya Tabata,&nbsp;Takehiro Tanaka,&nbsp;Tadashi Yoshino","doi":"10.3960/jslrt.22021","DOIUrl":"https://doi.org/10.3960/jslrt.22021","url":null,"abstract":"<p><p>It is difficult to histologically differentiate extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) from chronic gastritis (CG)/ reactive lymphoid hyperplasia (RLH). To determine whether immunohistochemistry for IRTA1 and MNDA can differentiate gastric MALT lymphoma from CG/RLH, we investigated 81 stomach biopsy specimens [Wotherspoon grade (WG) 1, 11 cases; WG 2, 9 cases; WG 3, 20 cases; WG 4, 31 cases; and WG 5, 10 cases]. According to a previously reported algorithm involving PCR for immunoglobulin heavy (IgH) chain locus rearrangement, all 81 cases were divided into three groups: CG/RLH (55 cases), MALT lymphoma (19 cases) groups, and IgH undetectable group (7 cases). We analyzed the CG/RLH and MALT lymphoma groups. The median percentage of IRTA1-positive cells was 0% (range 0%-90.6%) in the CG/RLH group and 43.5% (range 0%-97.6%) in the MALT lymphoma group (p < 0.0001). The median percentage of MNDA-positive cells was 32.4% (range 0%-97.6%) in the CG/RLH group and 55.1% (range 0%-97.6%) in the MALT lymphoma group (p = 0.0044). These results indicate that immunohistochemistry for IRTA1 and MNDA can help differentiate gastric MALT lymphoma from CG/RLH.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"62 4","pages":"195-201"},"PeriodicalIF":1.5,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c9/29/jslrt-62-195.PMC9898717.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10690107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Two cases of follicular lymphoma with MYC gene abnormalities that presented with bone marrow necrosis. 2例滤泡性淋巴瘤伴MYC基因异常,表现为骨髓坏死。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2022-12-28 DOI: 10.3960/jslrt.22004
Yuri Miyazawa, Hisashi Takei, Nobuhiko Kobayashi, Naoki Akashi, Yukiko Sairenji, Manato Sugisaki, Chiaki Naito, Tetsuya Ishikawa, Hiroaki Shimizu, Takuma Ishizaki, Akihiko Yokohama, Norifumi Tsukamoto, Yuka Yoshida, Nozomi Matsumura, Yoshiyasu Takayama, Hiroshi Handa

Bone marrow necrosis (BMN) occurs most frequently in hematological malignancies and sometimes in non-hematological disorders. Lymphoid diseases causing necrosis are regarded as high-grade disease. B-lymphoblastic leukemia/lymphoma is the most common malignant cause of BMN. Here, we present two patients with follicular lymphoma (FL) and MYC gene abnormalities who developed BMN. In one case of BMN, the necrosis disappeared in response to chemotherapy, and the patient survived with complete remission. In the other case, BMN remained even after chemotherapy, and effective chemotherapy could not be administered due to suppressed hematopoiesis, which led to the lymphoma worsening and the patient's death. Indolent lymphomas, such as FL, as in these cases, have the potential to develop BMN. It is important to detect the development of BMN and administer chemotherapy early to improve patient prognosis, since severe BMN prevents patients from receiving effective treatment.

骨髓坏死(BMN)最常见于血液系统恶性肿瘤,有时也见于非血液系统疾病。引起坏死的淋巴性疾病被认为是高级别疾病。b淋巴母细胞白血病/淋巴瘤是BMN最常见的恶性病因。在此,我们报告了两例滤泡性淋巴瘤(FL)和MYC基因异常并发BMN的患者。在一例骨髓性神经网络中,化疗后坏死消失,患者完全缓解。另一例患者化疗后BMN仍然存在,由于造血抑制无法给予有效的化疗,导致淋巴瘤恶化,患者死亡。惰性淋巴瘤,如FL,在这些病例中,有发展成BMN的潜力。由于严重的BMN使患者无法得到有效的治疗,因此早期发现BMN的发展并给予化疗对改善患者预后非常重要。
{"title":"Two cases of follicular lymphoma with MYC gene abnormalities that presented with bone marrow necrosis.","authors":"Yuri Miyazawa,&nbsp;Hisashi Takei,&nbsp;Nobuhiko Kobayashi,&nbsp;Naoki Akashi,&nbsp;Yukiko Sairenji,&nbsp;Manato Sugisaki,&nbsp;Chiaki Naito,&nbsp;Tetsuya Ishikawa,&nbsp;Hiroaki Shimizu,&nbsp;Takuma Ishizaki,&nbsp;Akihiko Yokohama,&nbsp;Norifumi Tsukamoto,&nbsp;Yuka Yoshida,&nbsp;Nozomi Matsumura,&nbsp;Yoshiyasu Takayama,&nbsp;Hiroshi Handa","doi":"10.3960/jslrt.22004","DOIUrl":"https://doi.org/10.3960/jslrt.22004","url":null,"abstract":"<p><p>Bone marrow necrosis (BMN) occurs most frequently in hematological malignancies and sometimes in non-hematological disorders. Lymphoid diseases causing necrosis are regarded as high-grade disease. B-lymphoblastic leukemia/lymphoma is the most common malignant cause of BMN. Here, we present two patients with follicular lymphoma (FL) and MYC gene abnormalities who developed BMN. In one case of BMN, the necrosis disappeared in response to chemotherapy, and the patient survived with complete remission. In the other case, BMN remained even after chemotherapy, and effective chemotherapy could not be administered due to suppressed hematopoiesis, which led to the lymphoma worsening and the patient's death. Indolent lymphomas, such as FL, as in these cases, have the potential to develop BMN. It is important to detect the development of BMN and administer chemotherapy early to improve patient prognosis, since severe BMN prevents patients from receiving effective treatment.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"62 4","pages":"208-216"},"PeriodicalIF":1.5,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9d/39/jslrt-62-208.PMC9898713.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10700330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cholesterol metabolism and lipid droplet vacuoles; a potential target for the therapy of aggressive lymphoma. 胆固醇代谢与脂滴液泡;治疗侵袭性淋巴瘤的潜在靶点。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2022-12-28 DOI: 10.3960/jslrt.22023
Hiromu Yano, Yukio Fujiwara, Yoshihiro Komohara

Cholesterol uptake via LDL receptor (LDLR) is increased in some malignant tumors, and incorporated LDL contribute to lipid droplet formation. Burkitt's lymphoma is known to have a large number of vacuoles in the cytoplasm, however, intracellular vacuoles are also seen in high-grade lymphomas such as adult T-cell leukemia/lymphoma, diffuse large B-cell lymphoma and primary central nervous system lymphoma. Recent studies have shown that esterified cholesterol is the main component of these vacuoles and the expression of cholesterol metabolism-related molecules such as LDLR, acetyl-CoA acetyltransferase 1 (ACAT1) which esterifies free cholesterol, and scavenger receptor class B type I (SR-BI) which effluxes free cholesterol, was significantly upregulated in lymphoma cells. Moreover, negative feedback of LDLR was not regulated even under cholesterol-rich conditions in lymphoma cells. We found that cytoplasmic free cholesterol was increased by ACAT and SR-BI inhibitors (CI-976 and BLT-1, respectively), and the accumulation of free cholesterol induced lymphoma cell apoptosis. In addition, overexpression of lipid droplet surface proteins has been correlated with poor prognosis in several malignant tumor such as ovarian cancer and clear cell renal cell carcinoma, and it is important to evaluate lipid droplet formation in malignant tumors including lymphomas.

在一些恶性肿瘤中,LDL受体(LDLR)对胆固醇的摄取增加,并掺入LDL有助于脂滴的形成。已知Burkitt淋巴瘤细胞质中有大量空泡,但在成人t细胞白血病/淋巴瘤、弥漫性大b细胞淋巴瘤和原发性中枢神经系统淋巴瘤等高级别淋巴瘤中也可见细胞内空泡。最近的研究表明,酯化胆固醇是这些空泡的主要成分,并且胆固醇代谢相关分子如LDLR,乙酰辅酶a乙酰转移酶1 (ACAT1)酯化游离胆固醇,以及排出游离胆固醇的清除率受体B类I型(SR-BI)在淋巴瘤细胞中的表达显著上调。此外,即使在富含胆固醇的淋巴瘤细胞中,LDLR的负反馈也不受调节。我们发现ACAT和SR-BI抑制剂(分别为CI-976和BLT-1)增加了细胞质游离胆固醇,并且游离胆固醇的积累诱导淋巴瘤细胞凋亡。此外,在卵巢癌、透明细胞肾细胞癌等多种恶性肿瘤中,脂滴表面蛋白的过表达与预后不良有关,对包括淋巴瘤在内的恶性肿瘤中脂滴形成的评估具有重要意义。
{"title":"Cholesterol metabolism and lipid droplet vacuoles; a potential target for the therapy of aggressive lymphoma.","authors":"Hiromu Yano,&nbsp;Yukio Fujiwara,&nbsp;Yoshihiro Komohara","doi":"10.3960/jslrt.22023","DOIUrl":"https://doi.org/10.3960/jslrt.22023","url":null,"abstract":"<p><p>Cholesterol uptake via LDL receptor (LDLR) is increased in some malignant tumors, and incorporated LDL contribute to lipid droplet formation. Burkitt's lymphoma is known to have a large number of vacuoles in the cytoplasm, however, intracellular vacuoles are also seen in high-grade lymphomas such as adult T-cell leukemia/lymphoma, diffuse large B-cell lymphoma and primary central nervous system lymphoma. Recent studies have shown that esterified cholesterol is the main component of these vacuoles and the expression of cholesterol metabolism-related molecules such as LDLR, acetyl-CoA acetyltransferase 1 (ACAT1) which esterifies free cholesterol, and scavenger receptor class B type I (SR-BI) which effluxes free cholesterol, was significantly upregulated in lymphoma cells. Moreover, negative feedback of LDLR was not regulated even under cholesterol-rich conditions in lymphoma cells. We found that cytoplasmic free cholesterol was increased by ACAT and SR-BI inhibitors (CI-976 and BLT-1, respectively), and the accumulation of free cholesterol induced lymphoma cell apoptosis. In addition, overexpression of lipid droplet surface proteins has been correlated with poor prognosis in several malignant tumor such as ovarian cancer and clear cell renal cell carcinoma, and it is important to evaluate lipid droplet formation in malignant tumors including lymphomas.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"62 4","pages":"190-194"},"PeriodicalIF":1.5,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3f/6d/jslrt-62-190.PMC9898721.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10700877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
An experience with ibrutinib monotherapy for Richter's syndrome isolated in the central nervous system. 伊鲁替尼单药治疗中枢神经系统孤立的里希特综合征的经验。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2022-12-28 DOI: 10.3960/jslrt.22017
Yuma Nato, Keiki Nagaharu, Kanako Inoue, Kodai Yabu, Akihiko Sawaki, Takuya Shiotani, Yuki Kageyama, Ken Tanaka, Koichi Ohshima, Hiroyuki Miyashita

Richter's syndrome (RS) of the central nervous system (CNS) is known to have an extremely poor prognosis. Ibrutinib has been reported to have some activity in patients with RS, despite its poor prognosis. Although ibrutinib crosses the blood-brain barrier, its efficacy in RS patients with CNS involvement remains unknown. Here, we report a case of RS isolated in the CNS that was confirmed to be clonally related to chronic lymphocytic leukemia (CLL) by immunoglobulin heavy chain gene analysis. Although the median survival of patients with RS clonally related to CLL was significantly shorter than that of patients with RS clonally unrelated to CLL, the patient received ibrutinib monotherapy without experiencing any significant adverse events, and the disease remained stable with ibrutinib until 6 weeks later. Following whole-brain radiation therapy (40 Gy in 20 fractions) with dexamethasone, the patient has survived for five months after diagnosis. Thus, ibrutinib may be a safe and effective therapeutic option for patients with RS and CNS involvement.

中枢神经系统(CNS)的里希特综合征(RS)已知预后极差。据报道,伊鲁替尼在RS患者中有一定的活性,尽管预后较差。尽管伊鲁替尼能穿过血脑屏障,但其对累及中枢神经系统的RS患者的疗效尚不清楚。在此,我们报告一例分离于中枢神经系统的RS,经免疫球蛋白重链基因分析证实与慢性淋巴细胞白血病(CLL)克隆相关。虽然与CLL克隆相关的RS患者的中位生存期明显短于与CLL克隆无关的RS患者,但该患者接受伊鲁替尼单药治疗后未发生任何明显不良事件,并且伊鲁替尼治疗后病情保持稳定,直至6周后。在用地塞米松进行全脑放射治疗(40 Gy,分20次)后,患者在诊断后存活了5个月。因此,依鲁替尼可能是RS和CNS受累患者安全有效的治疗选择。
{"title":"An experience with ibrutinib monotherapy for Richter's syndrome isolated in the central nervous system.","authors":"Yuma Nato,&nbsp;Keiki Nagaharu,&nbsp;Kanako Inoue,&nbsp;Kodai Yabu,&nbsp;Akihiko Sawaki,&nbsp;Takuya Shiotani,&nbsp;Yuki Kageyama,&nbsp;Ken Tanaka,&nbsp;Koichi Ohshima,&nbsp;Hiroyuki Miyashita","doi":"10.3960/jslrt.22017","DOIUrl":"https://doi.org/10.3960/jslrt.22017","url":null,"abstract":"<p><p>Richter's syndrome (RS) of the central nervous system (CNS) is known to have an extremely poor prognosis. Ibrutinib has been reported to have some activity in patients with RS, despite its poor prognosis. Although ibrutinib crosses the blood-brain barrier, its efficacy in RS patients with CNS involvement remains unknown. Here, we report a case of RS isolated in the CNS that was confirmed to be clonally related to chronic lymphocytic leukemia (CLL) by immunoglobulin heavy chain gene analysis. Although the median survival of patients with RS clonally related to CLL was significantly shorter than that of patients with RS clonally unrelated to CLL, the patient received ibrutinib monotherapy without experiencing any significant adverse events, and the disease remained stable with ibrutinib until 6 weeks later. Following whole-brain radiation therapy (40 Gy in 20 fractions) with dexamethasone, the patient has survived for five months after diagnosis. Thus, ibrutinib may be a safe and effective therapeutic option for patients with RS and CNS involvement.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"62 4","pages":"238-241"},"PeriodicalIF":1.5,"publicationDate":"2022-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ea/2e/jslrt-62-238.PMC9898719.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10690104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy. 血清IgG和淋巴细胞计数对于接受苯达莫司汀-利妥昔单抗治疗的患者早期发现感染是有用的。
IF 1.5 Q4 HEMATOLOGY Pub Date : 2022-06-28 Epub Date: 2022-03-12 DOI: 10.3960/jslrt.21031
Manabu Suzuki, Daisuke Koyama, Shohei Ikeda, Masumi Sukegawa, Mayumi Teshirogi, Kyohei Misawa, Saburo Tsunoda

Bendamustine-rituximab (BR) therapy has been established as a highly effective regimen for indolent non-Hodgkin lymphoma (NHL). However, patients who receive BR therapy exhibit persistent hypogammaglobulinemia and lymphopenia, resulting in an increased incidence of infections. As a sustained immunosuppressive state is a risk factor for infections, early predictive biomarkers for infections related to BR therapy need to be identified. We retrospectively analyzed 61 patients with indolent NHL who were followed up for 2 years after the end of BR therapy. Progression-free survival was significantly influenced by the incidence of infections. Patients with infections related to BR therapy exhibited persistent hypogammaglobulinemia and lymphopenia. In addition, we determined the cutoff values of serum IgG values and lymphocyte counts for infections using receiver operating characteristic curve analysis. Minimum serum IgG and lymphocyte counts at the first BR treatment cycle were significantly associated with the incidence of infections during and after BR treatment. Furthermore, the development of skin reactions during BR therapy was significantly associated with the incidence of infections after BR therapy. Our study suggested that these values and symptom are predictive biomarkers for infections related to BR therapy. Based on these findings, better management of indolent NHL patients will be possible.

苯达莫司汀-利妥昔单抗(BR)治疗已被确定为治疗惰性非霍奇金淋巴瘤(NHL)的高效方案。然而,接受BR治疗的患者表现出持续的低丙种球蛋白血症和淋巴细胞减少症,导致感染发生率增加。由于持续的免疫抑制状态是感染的危险因素,因此需要确定与BR治疗相关的感染的早期预测性生物标志物。我们回顾性分析了61例惰性NHL患者,他们在BR治疗结束后随访了2年。感染发生率显著影响无进展生存期。与BR治疗相关的感染患者表现出持续的低γ -球蛋白血症和淋巴细胞减少症。此外,我们使用受试者工作特征曲线分析确定血清IgG值和淋巴细胞计数的截止值。第一个BR治疗周期的最低血清IgG和淋巴细胞计数与BR治疗期间和治疗后的感染发生率显著相关。此外,BR治疗期间皮肤反应的发生与BR治疗后感染的发生率显著相关。我们的研究表明,这些值和症状是BR治疗相关感染的预测性生物标志物。基于这些发现,更好地管理惰性NHL患者将是可能的。
{"title":"Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy.","authors":"Manabu Suzuki,&nbsp;Daisuke Koyama,&nbsp;Shohei Ikeda,&nbsp;Masumi Sukegawa,&nbsp;Mayumi Teshirogi,&nbsp;Kyohei Misawa,&nbsp;Saburo Tsunoda","doi":"10.3960/jslrt.21031","DOIUrl":"https://doi.org/10.3960/jslrt.21031","url":null,"abstract":"<p><p>Bendamustine-rituximab (BR) therapy has been established as a highly effective regimen for indolent non-Hodgkin lymphoma (NHL). However, patients who receive BR therapy exhibit persistent hypogammaglobulinemia and lymphopenia, resulting in an increased incidence of infections. As a sustained immunosuppressive state is a risk factor for infections, early predictive biomarkers for infections related to BR therapy need to be identified. We retrospectively analyzed 61 patients with indolent NHL who were followed up for 2 years after the end of BR therapy. Progression-free survival was significantly influenced by the incidence of infections. Patients with infections related to BR therapy exhibited persistent hypogammaglobulinemia and lymphopenia. In addition, we determined the cutoff values of serum IgG values and lymphocyte counts for infections using receiver operating characteristic curve analysis. Minimum serum IgG and lymphocyte counts at the first BR treatment cycle were significantly associated with the incidence of infections during and after BR treatment. Furthermore, the development of skin reactions during BR therapy was significantly associated with the incidence of infections after BR therapy. Our study suggested that these values and symptom are predictive biomarkers for infections related to BR therapy. Based on these findings, better management of indolent NHL patients will be possible.</p>","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"62 2","pages":"91-98"},"PeriodicalIF":1.5,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ec/21/jslrt-62-91.PMC9353852.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39914331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Lymphomatoid gastropathy/NK-cell enteropathy involving the stomach and intestine 淋巴瘤样胃病/ nk细胞性肠病累及胃和肠
IF 1.5 Q4 HEMATOLOGY Pub Date : 2022-04-27 DOI: 10.3960/jslrt.21032
M. Nakajima, Masayuki Shimoda, K. Takeuchi, Akito Dobashi, T. Kanai, Y. Kanai, Y. Iwao
Lymphomatoid gastropathy (LyGa)/natural killer (NK)-cell enteropathy (NKCE) is recognized as a benign NK-cell lymphoproliferative disease. Due to its histological similarity to NK/T cell lymphoma, it is easy to misdiagnose, leading to unnecessary chemotherapy and poor quality of life. This disease is typically observed in the small and large intestines in North America, whereas almost all cases in Japan occur locally in the stomach. Only 11 LyGa/NKCE cases involving both gastric and intestinal lesions have been reported, and there are few reports providing endoscopic images throughout the gastrointestinal tract. We report a case of LyGa/NKCE involving both the stomach and small and large intestines with detailed upper gastrointestinal endoscopy, colonoscopy, capsule endoscopy and pathology images. Its pathogenesis currently remains elusive, but most patients with LyGa/NKCE in Japan have Helicobacter pylori (H. pylori) infection. Our patient was also positive for H. pylori infection at disease onset, but after receiving eradication therapy, ulcerative lesions in both stomach and intestine regressed and no recurrence was observed. This case suggests a link between the pathogenesis of LyGa/NKCE and H. pylori infection.
类淋巴瘤胃病(LyGa)/自然杀伤(NK)细胞肠病(NKCE)是公认的一种良性NK细胞淋巴增生性疾病。由于其与NK/T细胞淋巴瘤的组织学相似,容易误诊,导致不必要的化疗和生活质量下降。这种疾病通常在北美的小肠和大肠中观察到,而在日本几乎所有病例都发生在胃局部。仅报道了11例LyGa/NKCE同时涉及胃和肠道病变的病例,很少有报道提供整个胃肠道的内镜图像。我们报告一例LyGa/NKCE累及胃、小肠和大肠,并附详细的上消化道内镜、结肠镜、胶囊内镜和病理图像。其发病机制目前尚不清楚,但日本大多数LyGa/NKCE患者都感染了幽门螺杆菌(h.p ylori)。本例患者发病时幽门螺杆菌感染阳性,但在接受根除治疗后,胃和肠溃疡病变均消退,未见复发。本病例提示LyGa/NKCE的发病机制与幽门螺杆菌感染有关。
{"title":"Lymphomatoid gastropathy/NK-cell enteropathy involving the stomach and intestine","authors":"M. Nakajima, Masayuki Shimoda, K. Takeuchi, Akito Dobashi, T. Kanai, Y. Kanai, Y. Iwao","doi":"10.3960/jslrt.21032","DOIUrl":"https://doi.org/10.3960/jslrt.21032","url":null,"abstract":"Lymphomatoid gastropathy (LyGa)/natural killer (NK)-cell enteropathy (NKCE) is recognized as a benign NK-cell lymphoproliferative disease. Due to its histological similarity to NK/T cell lymphoma, it is easy to misdiagnose, leading to unnecessary chemotherapy and poor quality of life. This disease is typically observed in the small and large intestines in North America, whereas almost all cases in Japan occur locally in the stomach. Only 11 LyGa/NKCE cases involving both gastric and intestinal lesions have been reported, and there are few reports providing endoscopic images throughout the gastrointestinal tract. We report a case of LyGa/NKCE involving both the stomach and small and large intestines with detailed upper gastrointestinal endoscopy, colonoscopy, capsule endoscopy and pathology images. Its pathogenesis currently remains elusive, but most patients with LyGa/NKCE in Japan have Helicobacter pylori (H. pylori) infection. Our patient was also positive for H. pylori infection at disease onset, but after receiving eradication therapy, ulcerative lesions in both stomach and intestine regressed and no recurrence was observed. This case suggests a link between the pathogenesis of LyGa/NKCE and H. pylori infection.","PeriodicalId":45936,"journal":{"name":"Journal of Clinical and Experimental Hematopathology","volume":"9 1","pages":"114 - 118"},"PeriodicalIF":1.5,"publicationDate":"2022-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75034833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Journal of Clinical and Experimental Hematopathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1